Novo Nordisk Layoffs: 215 More Jobs Cut at US Headquarters in Sales Overhaul

Novo Nordisk layoffs infographic: 215 jobs cut at Plainsboro US headquarters

A new round of Novo Nordisk layoffs will remove 215 jobs at the Wegovy maker’s US headquarters in Plainsboro, New Jersey, according to a state Worker Adjustment and Retraining Notification (WARN) filing reported on 20 November 2026. The separations take effect between 17 and 19 February 2027. Combined with 108 cuts disclosed at the same site in late September, the Danish drugmaker has now announced 323 job losses at its American base in about two months, all tied to a redesign of its US sales organisation.

Key takeaways on Novo Nordisk layoffs

  • 215 Plainsboro roles end on 17-19 February 2027, per the New Jersey WARN notice.
  • This follows 108 cuts at the same headquarters disclosed in late September, for 323 in total.
  • Novo links both rounds to the September 2026 redesign of its US sales force.
  • Globally, CEO Mike Doustdar has said headcount fell by about 13,000 over the past year, including 9,000 layoffs announced in September 2025.
  • The cuts come as Novo fights Eli Lilly on price and access in the US obesity market.

Where the cuts fall

The filing sits in New Jersey’s 2026 WARN notice archive, which employers must use when a mass layoff or plant closing is planned. The law requires 90 days’ notice in New Jersey, which fits the mid-February effective dates. The notice does not break the 215 positions down by function, but Novo’s statement to BioSpace tied them to the sales overhaul it began in September. Plainsboro houses Novo’s US commercial, medical and support teams rather than manufacturing, so production of Ozempic and Wegovy is not directly affected.

RoundDisclosedJobs affectedScope
Global restructuringSeptember 2025About 9,000Worldwide
US HQ round 1Late September 2026108Plainsboro, NJ
US HQ round 220 November 2026215Plainsboro, NJ
US HQ total (by our calculation)2026323Plainsboro, NJ

Why Novo is reshaping its US sales force

The business logic is visible in how Novo now sells its GLP-1 medicines. A growing share of Wegovy volume in the US moves through cash-pay and direct-to-patient channels rather than through traditional rep visits to doctors’ offices. This month the company relaunched its NovoCare membership programme for Wegovy, with home delivery and fixed cash prices. Telehealth partners, employer deals and lower list prices all reduce the need for a large field force built for the insurance-driven model of the past.

Competition is the other driver. Eli Lilly’s Zepbound and Mounjaro have taken share since 2024, and Lilly’s oral orforglipron (Foundayo) was approved in 2026, putting pressure on Novo’s own Wegovy pill. Novo has responded with price moves and late-stage bets such as CagriSema, whose early-responder analysis was shown at ObesityWeek this month. Cutting overhead in the US helps protect margins while list prices fall.

A wider pattern in pharma commercial teams

Novo is not alone. AstraZeneca said this month it would remove about 600 US sales roles in respiratory and immunology as part of a $1.5 billion savings plan, as we covered in AstraZeneca job cuts. Large drugmakers are shifting money from rep-heavy promotion toward digital channels, direct pricing and pipeline spending, while US drug pricing policy and the Medicare negotiation programme squeeze revenue on older brands. Field sales and support jobs are the first place that shift shows up.

For Novo specifically, the 323 US headquarters cuts are small next to the roughly 13,000 fall in global headcount Doustdar has described, much of it from the 2025 restructuring plus retirements and attrition. The message to investors is consistent: a leaner organisation focused on obesity and diabetes, with costs trimmed wherever growth has slowed.

Market context: obesity drugs

Demand for obesity medicines is the backdrop to every Novo decision. Acumen Research and Consulting estimated the global anti-obesity drugs market at $2.1 billion in 2022 and projected $8.2 billion by 2032, a 14.6% compound annual growth rate, with prescription products holding the largest share and Asia-Pacific growing fastest. The report was last updated in September 2023, before the full surge in GLP-1 sales, and its scope may not capture products approved mainly for diabetes, so the figures are best read as a conservative baseline. Either way, growth is now coming with lower prices and more competitors, which is exactly the setting in which companies cut sales costs.

What remains unclear

  • Which teams are affected. The WARN notice gives counts, not job titles.
  • Whether more US cuts are coming. Novo has not said the sales redesign is complete.
  • Whether field-based reps outside New Jersey are affected. WARN filings in other states would show this.
  • How the savings will be used, whether for pricing, launches or the pipeline.

Watch Novo’s full-year results in early 2027 for updated cost guidance and any further restructuring charges. More coverage is in our industry insights section.

FAQ

How many jobs is Novo Nordisk cutting in New Jersey?

The latest WARN notice covers 215 jobs at the Plainsboro headquarters. Together with 108 cuts disclosed in September, that makes 323 in 2026.

When do the Novo Nordisk layoffs take effect?

Between 17 and 19 February 2027, according to the filing.

Will the layoffs affect Ozempic or Wegovy supply?

There is no sign of that. The cuts are at the US commercial headquarters and are linked to the sales reorganisation, not to manufacturing sites.

Why is Novo Nordisk cutting jobs?

Novo says it is redesigning its US sales organisation. The move comes as obesity drug prices fall, more sales shift to direct-to-patient channels and competition from Eli Lilly intensifies.

Sources: New Jersey Department of Labor WARN archive; BioSpace layoff tracker (20 November 2026); company statements. Market data: Acumen Research and Consulting, Anti-Obesity Drugs Market report. Not investment advice. Last updated 21 November 2026.

Leave a Reply

Your email address will not be published. Required fields are marked *